Skip to main content
Premium Trial:

Request an Annual Quote

Clinical Data's Fiscal '06 Revenue Grows 22 Percent As Acquisition Costs Turns Profit Into Loss

NEW YORK (GenomeWeb News) - Clinical Data today announced a $50.9 million loss for fiscal year 2006 compared to a profit of $3.4 million in fiscal 2005 due to an increase in operational expenses from the acquisitions of Genaissance Pharmaceuticals and Icoria.
For the 12 months ended March 31, Clinical Data reported revenues of $68.8 million, a 22-percent increase from $56.4 million in fiscal 2005. The increase included Genaissance and Icoria's operating results.
The company's traditional product business reported a 2-percent increase in revenue, to $50.6 million from $49.8 million a year ago.
Clinical Data's loss for the year was primarily a result of expensing $39.7 million for in-process research and development projects at Genaissance and Icoria at the time of the acquisition, the company said. The company also reported an increase in operation costs after the acquisitions.
The company had $20.8 million in cash as of March 31.

The Scan

Fertility Fraud Found

Consumer genetic testing has uncovered cases of fertility fraud that are leading to lawsuits, according to USA Today.

Ties Between Vigorous Exercise, ALS in Genetically At-Risk People

Regular strenuous exercise could contribute to motor neuron disease development among those already at genetic risk, Sky News reports.

Test Warning

The Guardian writes that the US regulators have warned against using a rapid COVID-19 test that is a key part of mass testing in the UK.

Science Papers Examine Feedback Mechanism Affecting Xist, Continuous Health Monitoring for Precision Medicine

In Science this week: analysis of cis confinement of the X-inactive specific transcript, and more.